Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCODONE AND ACETAMINOPHEN vs BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full mu-opioid receptor agonist, producing analgesia via activation of descending inhibitory pathways, while acetaminophen is a centrally acting analgesic and antipyretic, likely through inhibition of cyclooxygenase (COX) in the CNS and modulation of serotonergic pathways.
Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin and thromboxane synthesis, which leads to analgesic, antipyretic, and anti-inflammatory effects.
Management of moderate to moderately severe pain (FDA approved),Off-label: acute pain, postoperative pain
Migraine pain relief,Headache,Muscle aches,Menstrual cramps,Arthritis,Reduction of risk of myocardial infarction (low-dose)
Oral: 5-10 mg oxycodone (with 325-650 mg acetaminophen) every 4-6 hours as needed; maximum oxycodone 60 mg/day (for immediate-release) or acetaminophen 4000 mg/day. Titrate to pain control.
500-1000 mg orally every 4-6 hours as needed; maximum 4000 mg in 24 hours.
Oxycodone: 3-5 hours (immediate-release), 4.5-8 hours (extended-release). Acetaminophen: 1.5-3 hours. Clinical context: Half-life may be prolonged in hepatic impairment, elderly, and renal failure.
Aspirin half-life is 15-20 minutes due to rapid hydrolysis to salicylate. Salicylate terminal half-life is 2-3 hours at low doses, up to 15-30 hours at high doses or with toxicity. At analgesic doses (600-1000 mg), effective half-life is ~3-4 hours, requiring q4-6h dosing.
Oxycodone is extensively metabolized in the liver via CYP3A4 (primarily) and CYP2D6 (minor) to noroxycodone, oxymorphone, and other metabolites. Acetaminophen is metabolized in the liver mainly via glucuronidation and sulfation with a minor CYP2E1 pathway producing toxic NAPQI.
Primarily metabolized by hepatic esterases to salicylate; conjugation with glycine (salicyluric acid) and glucuronic acid (salicyl phenolic glucuronide) mainly in the liver; also metabolized by cytochrome P450 (CYP) enzymes (CYP2C9) to a lesser extent.
Oxycodone: renal (primarily as noroxycodone, oxymorphone, and conjugated metabolites; <10% unchanged). Acetaminophen: renal (85-90% as sulfate and glucuronide conjugates; 2-4% unchanged; 8-10% as cysteine and mercapturate conjugates). Biliary/fecal excretion: minor (<5% for both).
Renal excretion of salicylate and its metabolites (salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, gentisic acid). Approximately 90% of a dose is excreted renally; 10% via bile/feces. Excretion is dose- and p H-dependent: alkaline urine increases clearance.
Oxycodone: 38-45% (primarily to albumin). Acetaminophen: 10-25% (minimal binding).
80-90% bound to serum albumin, primarily binding site I (warfarin site). Binding is saturable and decreases at high concentrations, increasing free fraction and toxicity risk.
Oxycodone: 2.6-3.0 L/kg (wide distribution into tissues). Acetaminophen: 0.9-1.0 L/kg (uniformly distributed in body fluids).
0.15-0.2 L/kg for aspirin; for salicylate 0.1-0.2 L/kg. Low Vd reflects limited extravascular distribution; does not extensively penetrate brain except at high doses (therapeutic for migraine likely CNS penetration via passive diffusion).
Oral immediate-release: oxycodone 60-87%, acetaminophen 68-88%. Oral extended-release: oxycodone 60-87% (less variable). Rectal: variable (unspecified for this combination).
Oral immediate-release aspirin: 50-75% (due to first-pass hydrolysis in GI mucosa and liver). Enteric-coated: reduced and delayed absorption. Rectal: 20-50% (variable). For BAYER EXTRA STRENGTH ASPIRIN (500 mg), ~60% bioavailability.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: acetaminophen no change, oxycodone consider 75% of usual dose; Cr Cl 10-29 m L/min: acetaminophen extend interval to q6h, oxycodone consider 50% of usual dose; Cr Cl <10 m L/min: acetaminophen avoid or 650 mg q8h, oxycodone 50% of usual dose; hemodialysis: acetaminophen 650 mg q8h, oxycodone 25-50% of usual dose.
GFR 10-50 m L/min: avoid or reduce dose to 500 mg every 6 hours; GFR <10 m L/min: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: oxycodone reduce dose by 50%, acetaminophen maximum 2000 mg/day; Child-Pugh C: oxycodone reduce dose by 75%, acetaminophen maximum 2000 mg/day; severe hepatic impairment: avoid acetaminophen component.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% or extend interval to 8 hours; Class C: contraindicated.
Children ≥6 months: 0.05-0.15 mg/kg oxycodone (based on oxycodone component) every 4-6 hours, maximum single dose 5 mg; acetaminophen 10-15 mg/kg/dose, maximum 75 mg/kg/day (up to 4000 mg/day). Weight-based oxycodone not to exceed adult dose.
Weight <40 kg: 10-15 mg/kg orally every 4-6 hours, maximum 60 mg/kg/day; Weight ≥40 kg: adult dosing.
Start at 50% of adult dose (oxycodone 2.5-5 mg every 6 hours), titrate cautiously; maximum acetaminophen 3000 mg/day due to decreased hepatic reserves; monitor for renal impairment and avoid if Cr Cl <30 m L/min.
Start at lowest effective dose (500 mg every 6-8 hours); monitor renal function and bleeding risk.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome; accidental ingestion may be fatal; risk of hepatotoxicity with acetaminophen overdose.
Reye's syndrome: Aspirin should not be used in children or teenagers with viral infections due to risk of Reye's syndrome.
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; hepatotoxicity (acetaminophen); severe hypotension; adrenal insufficiency; seizures; increased risk of overdose in patients with head injury or COPD.
Increased risk of gastrointestinal bleeding, ulcers, and perforation; hypersensitivity reactions including anaphylaxis; increased bleeding risk; severe hepatic injury; caution in patients with asthma, G6PD deficiency, renal impairment, or history of peptic ulcer disease.
Hypersensitivity to oxycodone, acetaminophen, or any component; significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; known or suspected gastrointestinal obstruction; severe hepatic impairment (acetaminophen).
Hypersensitivity to aspirin or NSAIDs; active peptic ulcer disease; severe hepatic or renal impairment; bleeding disorders; patients with viral infections (children/teenagers) due to Reye's syndrome risk; third trimester of pregnancy.
Avoid alcohol consumption; increases risk of hepatotoxicity from acetaminophen and potentiates CNS depression. Grapefruit juice may increase oxycodone absorption; avoid concurrent use. High-fat meals can delay oxycodone peak concentration, potentially reducing rapid pain relief. No specific restrictions with other foods.
High-fat meals may delay absorption and reduce efficacy. Avoid alcohol to minimize GI bleeding risk. No significant food interactions beyond general GI irritation, but taking with food may improve tolerance.
First trimester: Risk of neural tube defects not significantly increased with therapeutic use; opioid dependence may increase risk of congenital malformations (e.g., gastroschisis). Second/third trimester: Chronic use may cause fetal opioid dependence, leading to neonatal abstinence syndrome (NAS). Late third trimester: Risk of respiratory depression in neonate if used near delivery.
First trimester: Epidemiologic studies suggest an increased risk of gastroschisis and possibly other congenital anomalies with use, though absolute risk is low. Second trimester: Avoid due to potential effects on fetal renal function and premature closure of ductus arteriosus, though risk is lower than third trimester. Third trimester: Contraindicated. Use in third trimester increases risk of premature closure of ductus arteriosus, oligohydramnios, and periventricular hemorrhage in the fetus; may prolong gestation and labor.
Excreted into breast milk in low concentrations. M/P ratio for oxycodone: 3.2:1; acetaminophen: approximately 1.0. Considered compatible with breastfeeding with caution; monitor infant for sedation and feeding difficulties. Avoid if maternal codeine use due to CYP2D6 ultrarapid metabolism concerns (though oxycodone less affected).
Aspirin (acetylsalicylic acid) is excreted into breast milk in low concentrations. Milk-to-plasma ratio (M/P) is approximately 0.03-0.11 for salicylate. No adverse effects in breastfeeding infants have been reported with occasional low doses. However, regular high-dose use may lead to accumulation and potential toxicity in the infant (e.g., Reye's syndrome). Avoid use during breastfeeding; if needed, use lowest effective dose and monitor infant for bruising, bleeding, or metabolic acidosis.
No standard dose adjustment required for maternal pharmacokinetic changes. Increased renal clearance in pregnancy may slightly reduce acetaminophen levels, but therapeutic effect maintained. Oxycodone metabolism via CYP3A4 and 2D6; pregnancy-induced enzyme changes may alter clearance, but clinical significance unclear. Use lowest effective dose, avoid NSAIDs if co-prescribed.
Aspirin pharmacokinetics in pregnancy: Increased renal clearance and plasma volume may lower salicylate concentrations. However, due to teratogenic risks, routine aspirin use is not recommended. For specific indications (e.g., preeclampsia prevention, antiphospholipid syndrome), low-dose aspirin (81 mg/day) is used without dose adjustment. For high-dose or anti-inflammatory doses (e.g., 650 mg every 4-6 hours), avoid entirely in pregnancy, especially in third trimester.
Maximum daily acetaminophen dose is 4000 mg from all sources; prescribed combination tablets contribute to this limit. Oxycodone immediate-release duration is 3-6 hours; avoid crushing extended-release formulations. Both components have abuse potential; screen for opioid use disorder. In renal impairment, adjust dosing interval for oxycodone; avoid in Cr Cl <30 m L/min. In hepatic impairment, the acetaminophen component may be hepatotoxic; avoid in severe disease. Coadministration with serotonergic agents may precipitate serotonin syndrome. Naloxone is the reversal agent for oxycodone; acetylcysteine for acetaminophen overdose.
For migraine pain, aspirin 500-1000 mg (equivalent to 2-4 tablets of Bayer Extra Strength) is recommended at onset. Note that aspirin is contraindicated in patients with a history of nasal polyps, angioedema, or bronchospasm with NSAIDs. Monitor for tinnitus or hearing loss as signs of salicylate toxicity. Avoid use within 48 hours of alcohol cessation therapy due to GI irritation.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not take other products containing acetaminophen (e.g., Tylenol, cold medications) to avoid exceeding the maximum daily dose of 4000 mg.,Avoid alcohol while taking this medication; liver damage risk increases with alcohol use.,Do not crush, break, or chew tablets; swallow whole to avoid rapid release of oxycodone.,This medication can cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Store securely out of sight and reach of children; dispose of unused medication via a drug take-back program.,Take with food if nausea occurs; avoid high-fat meals as they may delay absorption.,Do not stop abruptly; withdrawal symptoms may occur. Consult your doctor for a tapering schedule.
Take this medication at the first sign of migraine pain for best results.,Do not exceed 8 tablets (4000 mg aspirin) in 24 hours.,Avoid alcohol while taking aspirin to reduce risk of stomach bleeding.,Do not use if you have a history of stomach ulcers, bleeding disorders, or asthma triggered by aspirin.,Consult a doctor if your migraine does not improve after 1-2 doses or if you have severe symptoms.,Keep out of reach of children; Reye's syndrome warning if given to children or teenagers with viral illness.
"Phenobarbital, a potent inducer of cytochrome P450 (CYP) enzymes, particularly CYP3A4 and CYP2D6, significantly increases the hepatic metabolism of oxycodone, a prodrug that requires CYP3A4-mediated N-demethylation to noroxycodone and CYP2D6-mediated O-demethylation to oxymorphone for its analgesic effects. This induction reduces the systemic exposure and peak plasma concentration of active oxycodone and its active metabolite oxymorphone, leading to diminished analgesic efficacy and potential opioid withdrawal symptoms in patients on chronic opioid therapy. Clinically, patients may require substantially higher doses of oxycodone to achieve pain relief, increasing the risk of dose-related adverse effects if the interaction is not recognized."
"The co-administration of oxycodone, a mu-opioid receptor agonist, and gamma-hydroxybutyric acid (GHB), a central nervous system depressant with activity at GABA-B and GHB receptors, results in additive or synergistic respiratory depression and CNS depression. This interaction potentiates the risk of severe hypoventilation, coma, and fatal overdose, especially in non-tolerant users or at therapeutic doses. The combined sedation also increases the likelihood of hypotension, bradycardia, and impaired psychomotor function, necessitating extreme caution."
"The coadministration of oxycodone, a mu-opioid receptor agonist with central nervous system (CNS) depressant effects, and perampanel, a noncompetitive AMPA receptor antagonist that also causes CNS depression, produces additive sedative and respiratory depressant effects. This synergy increases the risk of excessive sedation, impaired cognitive function, and potentially life-threatening respiratory depression. Patients may experience profound somnolence, confusion, and an increased fall risk, necessitating dose adjustments or avoidance."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCODONE AND ACETAMINOPHEN vs BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN, answered by our medical review team.
OXYCODONE AND ACETAMINOPHEN is a Opioid Agonist that works by Oxycodone is a full mu-opioid receptor agonist, producing analgesia via activation of descending inhibitory pathways, while acetaminophen is a centrally acting analgesic and antipyretic, likely through inhibition of cyclooxygenase (COX) in the CNS and modulation of serotonergic pathways.. BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN is a NSAID / Antiplatelet that works by Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin and thromboxane synthesis, which leads to analgesic, antipyretic, and anti-inflammatory effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCODONE AND ACETAMINOPHEN and BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCODONE AND ACETAMINOPHEN is: Oral: 5-10 mg oxycodone (with 325-650 mg acetaminophen) every 4-6 hours as needed; maximum oxycodone 60 mg/day (for immediate-release) or acetaminophen 4000 mg/day. Titrate to pain control.. The standard adult dose of BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN is: 500-1000 mg orally every 4-6 hours as needed; maximum 4000 mg in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCODONE AND ACETAMINOPHEN and BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCODONE AND ACETAMINOPHEN is classified as Category D/X. First trimester: Risk of neural tube defects not significantly increased with therapeutic use; opioid dependence may increase risk of congenital malformations (e.g., gastroschisis). BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN is classified as Category D/X. First trimester: Epidemiologic studies suggest an increased risk of gastroschisis and possibly other congenital anomalies with use, though absolute risk is low. Second trimester: A. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.